A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Conditions

Alzheimer's Disease

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.

Ages
60 years - 85 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Eli Lilly and Company
Start Date
03/24/2021
End Date
03/09/2023

For more information about this study, contact:

Monica Canning-Ball

monica.canning-ball@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Adam Mecca, MD, PhD
Assistant Professor of Psychiatry; Associate Director, Alzheimer's Disease Research Unit; Faculty, Alzheimer's Disease Research Center (ADRC)

Sub-Investigators

Last Updated
11/17/2021
Study HIC
#2000028807

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information